DEA Revokes Colorado Doctor's Controlled Substance License
Published Date: 2/14/2025
Notice
Summary
Dr. Yogesh Patel from Colorado lost his DEA registration because he’s not allowed to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration starting early 2024. This means Dr. Patel can no longer legally prescribe or manage controlled drugs, affecting his medical practice and patients.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Patel
The DEA revoked Yogesh Patel, M.D.'s Certificate of Registration No. FP8684931, effective March 17, 2025. He can no longer lawfully prescribe, dispense, or handle controlled substances in Colorado, which affects his medical practice and his patients' access to controlled medications.
Pending DEA Applications Denied
The DEA denied any pending applications by Yogesh Patel, M.D., to renew or modify his registration and denied any other pending applications for additional registration in Colorado. This prevents him from restoring or obtaining DEA authority to handle controlled substances in Colorado.
15-Day Reconsideration Window
Dr. Patel may file a properly supported motion for reconsideration of the Agency's findings of fact within fifteen calendar days of the date of this Order by email to the DEA Office of the Administrator. A timely motion gives him an opportunity to dispute the Agency's finding that his Colorado license is restricted.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-02626, Provo River Project-Rate Order No. WAPA-221
The Provo River Project’s electric service rate formula is getting a fresh update starting April 1, 2025, and will stay in place until March 31, 2030. This change mainly updates contract details but keeps the same pricing method, so customers won’t see rate hikes—just smoother billing. If you get power from this project, expect annual updates to your charges every September.
Next: 2025-02631, Procurement List; Proposed Deletions
The government plans to remove some products and services from a special list that supports nonprofits employing people who are blind or severely disabled. This means a few cleaning supplies and maintenance jobs will no longer be reserved for these groups. If you want to share your thoughts, you have until March 16, 2025, to speak up!